Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Newron and Myung In Pharm have signed a licence agreement for evenamide, for schizophrenia treatment in South Korea.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.